Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

11/12/24 12:12:50 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $FDMT alert in real time by email

SC 13G/A 1 UnitedStates_13G__4DMolecula.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) 4D Molecular Therapeutics Inc (Title of Class of Securities) Common Stock (CUSIP Number) 35104E100 (Date of Event Which Requires Filing of this Statement) September 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: X Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, an* d for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of * the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 35104E100 (1) Names of reporting persons The Vanguard Group (2) Check the appropriate box if a member of a group (a) (see instructions) (b) X (3) SEC use only (4) Citizenship or place of organization Pennsylvania Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power 66,478 (7) Sole dispositive power 2,672,574 (8) Shared dispositive power 95,143 (9) Aggregate amount beneficially owned by each reporting person 2,767,717 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 5.32% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: 4D Molecular Therapeutics Inc Item 1(b) Address of issuer's principal executive offices: 5858 Horton Street Suite 455 Emeryville, CA 94608 Items 2(a)-2(c). Name, Address Of principal business office, and Citizenship of* persons filing: The Vanguard Group - 23-1945930 100 Vanguard Blvd. Malvern, PA 19355 2(d) Title of class of securities: Common Stock 2(e) CUSIP Number: 35104E100 Item 3. This statement is being filed pursuant to Rule 13d-1. An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E). Item 4. Ownership As of the close of business on September 30, 2024: (a) Aggregate amount beneficially owned: 2,767,717 (b) Percent of class: 5.32% (c) Number of shares as to which person has: 1. The Vanguard Group (a) Amount beneficially owned: 2,767,717 (b) Percent of class: 5.32% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 66,478 (iii) Sole power to dispose or to direct the disposition of: 2,672,574 (iv) Shared power to dispose or to direct the disposition of: 95,143 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following . Item 6. Ownership of More than 5 Percent on Behalf of Another Person. The Vanguard Group, Inc.'s clients, including investment companies registered u* nder the Investment Company Act of 1940 and other managed accounts, have the ri* ght to receive or the power to direct the receipt of dividends from, or the pro* ceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5* %. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, t* he securities referred to above were not acquired and are not held for the pur* pose of or with the effect of changing or influencing the control of the issuer* of the securities and were not acquired and are not held in connection with or* as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 12, 2024 THE VANGUARD GROUP By: /s/ Ashley Grim Name: Ashley Grim Title: Head of Global Fund Administration

Get the next $FDMT alert in real time by email

Recent Analyst Ratings for

$FDMT

Date	Price Target	Rating	Analyst
11/21/2024	$8.00	Underweight	Morgan Stanley
9/23/2024		Overweight → Neutral	Cantor Fitzgerald
4/15/2024	$45.00	Overweight	Barclays
4/15/2024	$459.00	Overweight	Barclays
2/7/2024	$81.00	Buy	Goldman
10/26/2023	$25.00	Outperform	RBC Capital Mkts
10/24/2023	$32.00	Overweight	Cantor Fitzgerald
10/18/2023	$24.00	Market Perform → Outperform	Leerink Partners

More analyst ratings

Amendment: SEC Form SC 13G/A filed by 4D Molecular Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for $FDMT

$FDMT Leadership Updates

Live Leadership Updates

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

$FDMT Press Releases

Fastest customizable press release news feed in the world

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

$FDMT SEC Filings

SEC Form 10-Q filed by 4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 8-K filed by 4D Molecular Therapeutics Inc.

$FDMT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Morgan Stanley initiated coverage on 4D Molecular Therapeutics with a new price target

4D Molecular Therapeutics downgraded by Cantor Fitzgerald

Barclays initiated coverage on 4D Molecular Therapeutics with a new price target

$FDMT Large Ownership Changes

This live feed shows all institutional transactions in real time.